Business Wire

CA-ALTIUM

9.2.2021 03:21:04 CET | Business Wire | Press release

Share
Altium Empowers High School STEM Teachers with a Virtual Electronic Design Curriculum and Tools

In September 2020, Altium LLC, the leading printed circuit board (PCB) software company, launched Upverter Education , a free distance learning initiative to support STEM educators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005934/en/

“Upverter Education has the opportunity to help high school STEM teachers transition into the virtual classroom. Our goal is to support the next generation of electronics designers of all economic levels by giving them access to free curriculum and professional tools today to prepare them for their innovative careers in the future,” explains Rea Callender, Executive Director of Upverter Education.

The Upverter Education initiative provides the curriculum and resources to guide users through the design, prototyping and manufacturing of electronics engineering concluding with the delivery of students hardware designs. Teachers can utilize the materials to supplement their existing lesson plans, either as standalone units or as a full, 4-6 week educational program.

The program centers around Altium’s Upverter , a free, web-based PCB design tool that’s easy to use in the distance-learning classroom. Upverter’s collaborative and remote capabilities align perfectly with the needs of STEM educators for guiding students through the electronics design process and their exploration of technology and engineering.

Since the launch, the Upverter Education team has formed strategic partnerships with schools around the country and collaborations with leaders in engineering education, including the American Society for Engineering Education, TRYEngineering, First Robotics, and NASA’s Robotics Alliance Project.

Schools within Elk Grove Unified, one of California’s largest school districts, have adopted the Upverter Education program, as well as the North Carolina School of Science and Mathematics (NCSSM), a two-year public residential high school in Durham, NC.

Marshall Massengill, robotics mentor and alumnus of NCSSM, explains how Upverter has been helping him promote remote learning statewide. “Currently with Covid-19, most of our students are spread throughout the state rather than living on campus. Upverter’s collaborative nature is helping transform the team and keep on working, just as we would normally in the lab.” The Upverter Teachers Guide provides step by step instructions for teachers to launch the program.

For Michael Rosales, Engineering and Science teacher at Elk Grove Unified Florin High School, Altium’s education program is already changing the way he teaches Principles of Engineering. “This is perfect for my class already--it allows the kids to look at virtual circuits before they create physical ones, and you can have multiple people working on one circuit together,” Rosales reports.

Educators are currently using the program to teach robotics, engineering, digital electronics design, principles of engineering and STEM intro classes. The Upverter Education team is also supporting high school students working on proposals for NASA’s CubeSat Launch Initiative program, extending the use of Upverter for small satellite payloads.

To see how teachers are using Upverter Education in the classroom, please visit: https://youtu.be/cJu0Qopwk2M

For a comprehensive overview of the Upverter Education distance learning program, please register for this informational webinar , scheduled for February 27, 2021.

About Upverter

Upverter is a free EDA system delivered in a web-browser, which enables students and educators to design, share, and review schematics and printed circuit boards. It provides the ability to generate a bill of materials, Gerber files, and 3D rendering. Upverter is an Altium brand. To learn more about Upverter and Upverter Education, visit https://education.upverter.com/ .

ABOUT ALTIUM

Altium LLC, a global software company headquartered in San Diego, CA is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

Social Media:

https://www.facebook.com/AltiumOfficial

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye